Drugs / DW4421-1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07382661 | Feb → May 2026 overdue | — | Daewon Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DW4421-1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07382661 ↗ |
| Route | Oral | “2 capsules will be orally administered” NCT07382661 ↗ |